Matinas BioPharma | Investor Presentation Deck | 31 slides

Matinas BioPharma · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

31
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
present_solution
04
The slide illustrates the self-assembly of Phosphatidylserine (PS) and Calcium ions into a cochleate structure.present_solution
05
The slide uses a biological process diagram to illustrate how LNCs (Lipid Nanocochleates) leverage PS to enter cells.present_solution
06
The slide uses a comparative structure to explain two distinct biological pathways for drug delivery.present_solution
07
Uses a visual arrow-based timeline to show progression.plan_implementation
08
The slide uses a checkmark/cross system to visually demonstrate the superiority of LNCs.compare_peers
09
The slide uses a Gantt-style chart to map drug programs against development stages.plan_implementation
10
transition
11
The diagram uses a hub-and-spoke model to define the 'ideal' product profile.present_solution
12
present_solution
Open slide detailBeat · Solution
13
Includes medical imagery of fungal cells and brain infection.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
14
The slide details the dosing regimens for different cohorts over induction and consolidation phases.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
15
The slide uses a process-flow diagram to present five key clinical findings.show_traction
Open slide detailBeat · Traction
16
The chart uses a vertical dotted line at 0.2 to denote a clinical efficacy threshold.compare_peers
Open slide detailBeat · Traction
17
Includes n/N counts and specific clinical trial footnotes regarding patient outcomes and data status.analyze_data
Open slide detailBeat · Traction
18
Each patient is represented by a timeline showing rapid decline in fungal load from screening to final visit day.show_traction
Open slide detailBeat · Traction
19
show_traction
Open slide detailBeat · Traction
20
Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.plan_implementation
Open slide detailLoop · Quick Win Big Bet
21
The slide uses a chevron-based timeline to illustrate the lifecycle management strategy.present_solution
Open slide detailLoop · Quick Win Big Bet
22
Includes MIC comparison, tissue fungal burden (lung/brain), and survival curves.present_solution
23
The slide uses a map of the US to anchor the revenue projection and a list of four comparable deals to establish market precedent.size_opportunity
Open slide detailBeat · Market Sizing
24
transition
25
The slide highlights clinical safety and pharmacokinetic success for an oral formulation of amikacin.show_traction
26
Data presented as three distinct charts: line graph for weight, dot plot for congestion, and dot plot for viral titers.show_traction
27
The slide highlights a $2.75M upfront payment and the strategic synergy between Matinas' LNC platform and BioNTech's mRNA expertise.show_traction
28
The slide emphasizes long-term exclusivity through both patent filings and regulatory status (QIDP/ODD).present_solution
29
other
Open slide detailBeat · Team
30
Uses checkmarks for completed items and circular arrows for upcoming/potential items.plan_implementation
31
front_matter